Fuzeon (Enfuvirtide) - Summary

FUZEON SUMMARY

FUZEON (enfuvirtide) is an inhibitor of the fusion of HIV-1 with CD4 + cells. Enfuvirtide is a linear 36-amino acid synthetic peptide with the N-terminus acetylated and the C-terminus is a carboxamide. It is composed of naturally occurring L-amino acid residues.

FUZEON in combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

FUZEON NEWS HIGHLIGHTS

Media Articles Related to Fuzeon (Enfuvirtide)

Scientists Spot New Twist in HIV Infection (HealthDay)
Source: Y! Health News Search RSS Feed [2008.09.04]

CDC Report On New HIV Infections In U.S. Did Not Include Data From Puerto Rico; Omission Has Widespread Consequences, Advocates Say
Source: HIV / AIDS News From Medical News Today [2008.09.03]

In NYC, new HIV infections 3 times national rate (AP)
Source: Y! Health HIV & AIDS News [2008.08.27]

Number of New U.S. HIV Infections Gets Revised Upward
Source: MedicineNet Human Immunodeficiency Virus (HIV, AIDS) Specialty [2008.08.04]

Herpes Suppression May Not Prevent HIV Infection
Source: MedicineNet Genital Herpes In Women Specialty [2008.06.20]

more>>

Published Studies Related to Fuzeon (Enfuvirtide)

Adherence to enfuvirtide and its impact on treatment efficacy. [2008.02]

A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study). [2008]

Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration. [2006.12]

Viral Decay Dynamics in HIV-Infected Patients Receiving Ritonavir-Boosted Saquinavir and Efavirenz With or Without Enfuvirtide: A Randomized, Controlled Trial (HIV-NAT 012). [2006.11.01]

HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. [2006.07.15]

more>>

Clinical Trials Related to Fuzeon (Enfuvirtide)

Cohort Study for Patients Using Fuzeon (Enfuvirtide) [Active, not recruiting]

WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV. [Completed]

ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression. [Terminated]

AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. [Active, not recruiting]

Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide Resistance [Active, not recruiting]

more>>